m RNA-1273

URI: https://gptkb.org/entity/m_RNA-1273

GPTKB entity

Statements (56)

Predicate	Object
gptkbp:instance_of	gptkb:vaccine
gptkbp:accessories	gptkb:Yes
gptkbp:approves	December 18, 2020
gptkbp:average_temperature	-20 degrees Celsius
gptkbp:brand	gptkb:Spikevax
gptkbp:clinical_data_published	gptkb:New_England_Journal_of_Medicine
gptkbp:clinical_trial	Phase 3 30,420
gptkbp:clinical_trial_end_date	October 23, 2020
gptkbp:clinical_trial_start_date	July 27, 2020
gptkbp:cold_chain_requirements	gptkb:Yes
gptkbp:developed_by	Moderna, Inc.
gptkbp:distribution	Global
gptkbp:dosage_form	gptkb:Yes Two doses
gptkbp:emergency_services	gptkb:U._S._Food_and_Drug_Administration
https://www.w3.org/2000/01/rdf-schema#label	m RNA-1273
gptkbp:is_effective_against	94.1%
gptkbp:is_vulnerable_to	gptkb:Significant Intramuscular injection December 2020 Reduced hospitalization rates Rapid development Collaboration with governments Safety monitoring ongoing m RNA technology CDC guidelines U. S. government funding First m RNA vaccine authorized for use. Freezer or refrigerator High against variants Limited initially RNA vaccine Reduces severe disease
gptkbp:manufacturer	Moderna, Inc.
gptkbp:market	Ongoing
gptkbp:mechanism_of_action	induces an immune response
gptkbp:regulatory_compliance	Multiple countries
gptkbp:safety_features	Generally well-tolerated
gptkbp:side_effect	gptkb:Fever Fatigue Headache Joint pain Muscle pain
gptkbp:targets	gptkb:COVID-19
gptkbp:type	messenger RNA vaccine
gptkbp:vaccine_clinical_trial_location	gptkb:United_States
gptkbp:vaccine_clinical_trial_results	Published in peer-reviewed journals
gptkbp:vaccine_distribution_start_date	December 2020
gptkbp:vaccine_global_distribution	gptkb:Yes
gptkbp:vaccine_production	Increased over time
gptkbp:vaccine_public_acceptance	gptkb:High
gptkbp:vaccine_research_continued	gptkb:Yes
gptkbp:whoemergency_use_listing	gptkb:Yes
gptkbp:bfsParent	gptkb:Moderna
gptkbp:bfsLayer	5